Showing results (341-350 of 415) with videos related to

Sort By:
Pageof 42
Blood|June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCLJeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM StudyManali Kamdar, Scott R Solomon, Jon Arnason, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2021
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
JCI Insight|May 7, 2024
BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-αDiego A Vargas-Blanco, Olivia W Hepworth, Kyle J Basham, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
JACC. Heart Failure|July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesCarlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Pageof 42